Chronic myeloid leukemia (CML) is the first malignancy to be associated with a specific and consistent chromosomal abnormality. Present in >90% of CML patients, the Philadelphia (Ph) chromosome is the product of a t(9;22)(q34;q11) reciprocal translocation, leading to a fusion between the ABL proto-oncogene to the BCR breakpoint cluster region.
experience complete cytogenetic remission. 1 Imatinib's efficacy is due to the inhibition of the Bcr-Abl protein, with the drug occupying the TK domain and effectively negating the influence of the fusion protein on the cell cycle. In spite of imatinib's great success, resistance is a common problem, especially in the accelerated and blast crisis phases of CML. 5 Primary hematological resistance is rare (2-4% of all resistance cases) and poorly understood. Primary cytogenetic resistance is slightly more common, with 15-25% of patients failing to exhibit the desired effect within six to eight months of starting imatinib therapy. 6 Another 4% of patients are estimated to develop secondary resistance each year; 6 many of these cases have been associated with either acquired escape mutations in the Bcr-Abl kinase domain, allowing the protein to evade imatinib binding, or genomic amplification and continued overexpression of BCR-ABL.
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Although imatinib is not a curative therapy, it has been proved to prolong survival in patients with CML. Dasatinib (Sprycel, Bristol-Myers Squibb) and nilotinib (Tasigna, Novartis) have recently been approved by the US Food and Drug Administration (FDA) for the treatment of imatinibresistant or -intolerant CML patients; although active against most imatinib-resistant ABL mutants with demonstrated minimal crossresistance, there are still documented reports of resistance against these second-generation ABL kinase inhibitors. 12 These drug resistances to imatinib and its successors pose significant barriers in treatment and emphasize the need for novel therapies.
Acetylation Status and Cancer
In response to the demand for novel therapies, much drug development has focused on epigenetic targets. Among these are the post- families. Acetylation can effectively modify chromatin topology and the accessibility of transcription machinery to DNA, thereby modifying the degree of gene transcription. HATs and HDACs can also modify the acetylation of lysine residues in transcription factors. 13 This allows HATs and HDACs, by recruitment to promoter sites by transcriptional protein complexes, to regulate gene expression in a mechanism separate from that of chromatin remodeling. Some HDACs are also known to deacetylate non-histone, non-transcription factor proteins; among these are the nuclear import protein importin-α7, 14 signal transduction protein β-catenin, 15 the cytoskeletal protein α-tubulin, 16 and Ku70 and WRN, enzymes involved in DNA repair. 17, 18 More recently, HDAC has been found to deacetylate heat shock protein 90 (hsp90). 19, 20 It is therefore possible that HDACs may not affect gene transcription exclusively, potentially also modifying proteins involved in important cellular pathways.
Aberrant HDAC-dependent transcriptional repression has been implicated as a main pathogenic mechanism in several cancers, including lymphoma and forms of myeloid leukemias. 21, 22 The BCL6 transcriptional repressor functions through recruitment of HDAC and nuclear receptor co-repressors, but in non-Hodgkin's lymphoma lack of repression and overexpression of BCL6 result in lymphoid oncogenic transformation. 23 In the M2 subtype of acute myeloid leukemia (AML), the AML1-ETO fusion protein is formed as a result of a t(8;21)(q22;22) translocation. Where AML1 will typically activate gene expression to induce differentiation in a protein complex, the recruitment of HDAC to the protein complex by AML1-ETO causes the fusion protein to act as a potent transcriptional repressor. 24 The PML-RAR-α fusion protein is an oncoprotein associated with a chromosomal translocation t(15;17)(q22;21) in acute promyelocytic leukemia (APL), a subtype of AML. PML-RAR-α associates with the NCor-mSin3-HDAC transcriptional co-repressor complex to repress gene transcription and block the maturation in the myeloid line. 25 In each of these examples, recruitment of HDACs appears to mediate transcriptional deregulation, providing the rationale for treatment of hematological malignancies by inhibition of HDAC activity.
Cellular Mechanisms of Histone Deacetylase Inhibitors

Inhibition in Cell Cycle and Growth
In vitro, HDAC inhibitors (HDIs) cause cell-cycle arrest in G1 or G2, as well as differentiation and/or apoptosis in cultured transformed cells. can induce cell death dependent and independent of caspase pathways, but the latter mechanism using calpain activity has yet to be observed in other cell types. Moreover, LAQ824 in combination with imatinib was highly effective in inducing apoptosis in CML CD34 + cells. The LAQ824/imatinib combination also resulted in enhanced apoptosis of non-dividing CML CD34 + cells. 49 In vitro treatment combining SAHA and dasatinib can increase apoptosis and depletion of Bcr-Abl levels compared with either agent alone, while also attenuating levels of Bcr-Abl escape mutants. 50 Similarly, a combination therapy of nilotinib and LBH589 was found to be active against imatinib-resistant CML cells, inducing a greater loss of cell viability in these targets than either agent alone. 51 These early data support the in vivo testing of combination therapy in CML patients both sensitive and resistant to imatinib. 
